JIANGSU HENGRUI MEDICINE CO., LTD
SSE or SZSE Delayed Price. Currency in CNY
|Number of Shares|
|Company Name||JIANGSU HENGRUI MEDICINE CO., LTD|
|MSCI Security Code|
- Jan 6 , 2018
Hengrui Medicine Signs USD223 Mln Deal to Sell Right for Its Skin Diseases Immunotherapy Drug Development in US, EU, JapanJiangsu Hengrui Medicine Co. will sell to a US biotechnology company the exclusive right to clinically develop, register and market an immunotherapy drug for skin diseases, which it developed independently, in the US, the European Union and Japan.
- Sep 5 , 2017
Hengrui Medicine Gets FDA Go-Ahead to Make, Market New Drug in USJiangsu Hengrui Medicine Co. [SHA:600276] recently received an approval notice from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for a Cisatracurium Besylate Injection, Hengrui Medicine said yesterday.
- Aug 15 , 2017
Hengrui Medicine Gains FDA Approval to Make, Sell Generic Cancer Drug in US(Yicai Global) Aug. 15 -- The US Food and Drug Administration has approved the production and sale of docetaxel made by China’s Jiangsu Hengrui Medicine Co. [SHA:600276], in America, the firm said at a press briefing on Aug. 14. The docetaxel injection is microtubule inhibitor which can be used to treat breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and squamous cell carcinoma of the head and neck, among others.
- Jun 26 , 2017
Chinese Pharma Firm Hengrui Medicine Opens USD220 Million Subsidiary in SuzhouChinese pharmaceutical firm Jiangsu Hengrui Medicine Co. [SHA:600276] has invested USD220 million (CNY1.5 billion) to set up a subsidiary, Suzhou Shengdi Pharmaceutical Co., in Suzhou.